GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 80 filers reported holding GRITSTONE ONCOLOGY INC in Q3 2022. The put-call ratio across all filers is 0.63 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $85,776 | -70.4% | 49,870 | -58.3% | 0.00% | – |
| Q2 2022 | $290,000 | -13.2% | 119,645 | +47.6% | 0.00% | – |
| Q1 2022 | $334,000 | -48.0% | 81,064 | +62.3% | 0.00% | – |
| Q4 2021 | $642,000 | -70.1% | 49,932 | -74.9% | 0.00% | -100.0% |
| Q3 2021 | $2,149,000 | -71.2% | 198,924 | -75.6% | 0.00% | -75.0% |
| Q2 2021 | $7,451,000 | +3644.2% | 816,059 | +3772.2% | 0.00% | – |
| Q1 2021 | $199,000 | -61.5% | 21,075 | -84.0% | 0.00% | – |
| Q4 2020 | $517,000 | +27.3% | 131,363 | -14.2% | 0.00% | – |
| Q3 2020 | $406,000 | -51.1% | 153,086 | +22.3% | 0.00% | -100.0% |
| Q2 2020 | $831,000 | +151.1% | 125,167 | +120.2% | 0.00% | – |
| Q1 2020 | $331,000 | -35.5% | 56,849 | -0.9% | 0.00% | – |
| Q4 2019 | $513,000 | +27.6% | 57,357 | +22.7% | 0.00% | – |
| Q3 2019 | $402,000 | -7.2% | 46,748 | +19.7% | 0.00% | – |
| Q2 2019 | $433,000 | +13.6% | 39,070 | +36.0% | 0.00% | – |
| Q1 2019 | $381,000 | -15.0% | 28,729 | -1.1% | 0.00% | – |
| Q4 2018 | $448,000 | – | 29,056 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $9,152,000 | 15.60% |
| Frazier Life Sciences Management, L.P. | 5,237,348 | $13,460,000 | 1.04% |
| Redmile Group, LLC | 6,952,760 | $17,869,000 | 0.69% |
| Palo Alto Investors LP | 2,330,504 | $5,989,000 | 0.47% |
| ACT CAPITAL MANAGEMENT, LLC | 47,500 | $122,000 | 0.17% |
| SkyOak Wealth, LLC | 132,851 | $341,000 | 0.12% |
| Artal Group S.A. | 750,000 | $1,928,000 | 0.08% |
| CORNERCAP INVESTMENT COUNSEL INC | 77,046 | $198,000 | 0.04% |
| CAXTON ASSOCIATES LP | 95,190 | $245,000 | 0.03% |
| XTX Topco Ltd | 50,517 | $130,000 | 0.03% |